Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
about
Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Predictors of anticoagulation in hospice patients with lung cancer.Biosimilars of low-molecular-weight heparin products: fostering competition or reducing 'biodiversity'?Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerationsRole of parnaparin in atherosclerosis.Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.Preventing venous thromboembolism following orthopedic surgery in the United States: impact of special populations on clinical outcomes.Pharmacodynamics of multi-dose low molecular weight heparin in healthy horses.The Role of Tinzaparin in Oncology.Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?Cesarean delivery in the obese parturient: anesthetic considerations.Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?
P2860
Q30438893-D25C64CE-CA54-4272-8BB6-B7F55C43E6B9Q35156374-F7A79179-F8F0-41FC-9B20-D6C6FA01745EQ35880101-C388DB00-B33F-40E9-94C5-392C484173BCQ37844143-56919DF8-3BB9-493B-B604-803024F82906Q38707885-DCAC4FE2-E416-4514-A04B-B7844284B89FQ38958355-C77C6C9D-3E4B-408B-84FF-FCE999981E55Q40284785-7855DEE0-8B94-4458-B90A-D608FA56E078Q43108541-7B2EDA7B-5E74-4D1A-99F2-48B4680E3347Q43563791-49D6039A-3EF1-4397-825B-28F91CA3F584Q46064928-A74E68A5-88FA-49FB-AFC8-AE7DB4C435BCQ47681124-DE503C77-E179-4F83-B597-FB7A648D2C60Q48238213-B3007EDD-0A1D-4417-860B-07334BC9252AQ48278730-588119CC-92DC-47A0-87F7-679C1D0F5A3DQ50323429-254759F0-CA03-43F4-B46E-174A1D0FE8AB
P2860
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
@en
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
@nl
type
label
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
@en
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
@nl
prefLabel
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
@en
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
@nl
P1433
P1476
Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
@en
P2093
P304
P356
10.1016/J.THROMRES.2008.08.005
P478
123 Suppl 1
P577
2008-09-21T00:00:00Z